Bone Other Operating Expenses from 2010 to 2024

BBLGW Stock  USD 28.49  3.29  10.35%   
Bone Biologics Other Operating Expenses yearly trend continues to be fairly stable with very little volatility. Other Operating Expenses is likely to outpace its year average in 2024. Other Operating Expenses is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. View All Fundamentals
 
Other Operating Expenses  
First Reported
2008-12-31
Previous Quarter
903.5 K
Current Value
809.7 K
Quarterly Volatility
1.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Ebitda of 503.6 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Check out the analysis of Bone Biologics Correlation against competitors.

Latest Bone Biologics' Other Operating Expenses Growth Pattern

Below is the plot of the Other Operating Expenses of Bone Biologics Corp over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bone Biologics Corp. It is also known as Bone Biologics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Bone Biologics' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
Other Operating Expenses10 Years Trend
Slightly volatile
   Other Operating Expenses   
       Timeline  

Bone Other Operating Expenses Regression Statistics

Arithmetic Mean4,377,198
Geometric Mean510,868
Coefficient Of Variation123.19
Mean Deviation4,221,940
Median2,626,592
Standard Deviation5,392,256
Sample Variance29.1T
Range17.8M
R-Value0.32
Mean Square Error28.1T
R-Squared0.10
Significance0.25
Slope384,896
Total Sum of Squares407.1T

Bone Other Operating Expenses History

20249.9 M
20239.4 M
20223.7 M
20211.1 M
2020825 K
20192.4 M
20182.8 M

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Other Operating Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Operating Expenses9.4 M9.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.